| 摘要 |
The present invention provides substantially purified cryptdin peptides having a consensus amino acid sequence: X1-C-X2-C-R-X3-C-X4-E-X5-C-X6-C-C-X7wherein X1 is 3 to 9 amino acids; X2 is one amino acid, preferably Y, H or R; X3 is 2 or 3 amino acids; X4 is three amino acids; X5 is five amino acids; X6 is 6 to 10 amino acids; and X7 is 0 to 9 amino acids. The invention also provides a substantially purified mouse cryptdin having a consensus amino acid sequence: X1-L-X2-C-Y-C-R-X3-C-K-X4-E-X5-G-T-C-X6-C-C-X7wherein X1 is 3 or 4 amino acids, preferably LRD, LSKK (SEQ ID NO: 1) or LRG; X2 is 1 amino acid, preferably V, L or I; X3 is 3 amino acids, preferably KGH or *RG, where * is S, T, K, I or A; X4 is 2 amino acids, preferably GR, RR or RG; X5 is 3 amino acids, preferably RMN, RVR, RVF HMN or HIN; X6 is 6 to 9 amino acids, preferably GIRFLY (SEQ ID NO: 2) or RNLFLTFVF (SEQ ID NO: 3), RRGHLMYTL (SEQ ID NO: 4) or RKGHL*YT* (SEQ ID NO: 5), where * independently is L or M; and X7 is 0 to 3 amino acids, preferably R, S or PRR. The invention also provides cryptdin analogs, devoid of one or more amino acids N-terminal to the first cysteine. In addition, the invention provides nucleic acid molecules encoding cryptdin peptides. The invention further provides methods for detecting inflammatory pathologies in a subject and for treating an inflammatory pathology in a subject by administering a pharmaceutical composition containing a cryptdin peptide.
|
